eladocagene exuparvovec
Generic: eladocagene exuparvovec·Brand: Kebilidi
eladocagene exuparvovec: developed by 1 company · 1 clinical trial tracked.
eladocagene exuparvovec evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect eladocagene exuparvovec to PTCT; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could eladocagene exuparvovec → PTCT affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Aromatic L-Amino Decarboxylase (AADC) deficiency
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| PTC THERAPEUTICS, INC. (PTCT) Aromatic L-Amino Decarboxylase (AADC) deficiency | Approved |
Clinical Trials (1)
An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects
Primary endpoint: Change From Baseline in HVA Metabolite Level at the End of the Trial Phase
Interventionalopen13 targetStarted 2021-05Completion 2028-046 sites · Israel, Taiwan, United StatesPTC Therapeutics
Frequently asked questions
Who is developing eladocagene exuparvovec?
eladocagene exuparvovec is being developed by PTC THERAPEUTICS, INC..
How many clinical trials involve eladocagene exuparvovec?
BioSniper tracks 1 clinical trial involving eladocagene exuparvovec.